Can a Real-World registry improve how treprostinil is used for PAH?

NCT ID NCT07736846

Not yet recruiting Disease control Sponsor: AOP Orphan Pharmaceuticals AG Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This registry follows adults newly diagnosed with pulmonary arterial hypertension (PAH) who are starting treatment with parenteral treprostinil, a medication given as a continuous infusion under the skin or into a vein. Researchers will collect data from routine care—including dosing, side effects, and how well patients are doing—over at least three years. The goal is to understand how treprostinil is actually used in practice and what outcomes patients experience.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: treprostinil given as a continuous infusion under the skin or into a vein
What this could lead to: If successful, this registry could provide a clearer picture of how treprostinil works in everyday practice, helping doctors optimize treatment for people with PAH.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care across centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION (PAH)

More trials for these conditions

Other studies related to the condition(s) this trial covers.